Supplementary Table 2

1. Univariable meta-regression analyses

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Treatment outcome | Year of trial commencement | Rate of increase (%) | 95% CI | | | *P* | R2† |
| Tumor objective response rate | Every single later year commencement | 0.31 | | 0.01 | 0.05 | .046 | 16% |
| 3-month progression-free survival rate | Every single later year commencement | 0.51 | | -0.11 | 1.14 | .11 | 4% |
| 9-month overall survival rate | Every single later year commencement | 0.87 | | 0.38 | 1.35 | <.001 | 24% |

Univariable meta-regression analyses of year of study commencement with treatment outcomes

†R2 refers to heterogeneity in treatment outcomes explained by year of study commencement

1. Multivariable meta-regression analyses

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Treatment outcome† | Baseline factors‡ | Rate of increase (%) | 95% CI | | *P* |
| Tumor objective response rate | % of squamous histology | -0.08 | -0.15 | -0.01 | .02 |
|  | % of performance status 0 or 1 | 0.19 | 0.06 | 0.31 | .004 |
| 9-month overall survival rate | % of squamous histology | -0.25 | -0.41 | -0.09 | .003 |
|  | % of performance status 0 or 1 | 0.39 | 0.12 | 0.67 | .006 |

Best models of multivariable meta-regression analyses retaining only factors associated with treatment outcomes.

†No baseline factors were significantly associated with 3-month progression-free survival rate in multivariable meta-regression analyses

‡Year of trial commencement, % patients with squamous histology, % patients with performance status 0 or 1, % male patients, % patients undergoing second-line therapy were univariably associated with treatment outcomes and hence considered in multivariable analyses